Valbiotis SA (EPA:ALVAL)

France flag France · Delayed Price · Currency is EUR
0.8200
-0.0100 (-1.20%)
Nov 20, 2025, 5:35 PM CET
-1.20%
Market Cap19.63M
Revenue (ttm)474.00K
Net Income (ttm)-11.12M
Shares Out23.66M
EPS (ttm)-0.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume863,023
Average Volume607,116
Open0.8310
Previous Close0.8300
Day's Range0.7700 - 0.8650
52-Week Range0.5350 - 1.6760
Beta-0.41
RSI61.92
Earnings DateOct 30, 2025

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laborato... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 44
Stock Exchange Euronext Paris
Ticker Symbol ALVAL
Full Company Profile

Financial Performance

In 2024, Valbiotis's revenue was 176,000, a decrease of -96.28% compared to the previous year's 4.73 million. Losses were -10.03 million, 36.1% more than in 2023.

Financial Statements

News

There is no news available yet.